Burden of Chronic weight management
2 evidence topics · 22 sources
Summary: definition, epidemiology, mortality, and morbidity
The World Health Organization defines overweight in adults as a body mass index (BMI) of 25 or greater and obesity as a BMI of 30 or greater, and its 2026 guideline describes obesity as “a chronic, relapsing disease”. The Lancet Diabetes and Endocrinology Commission defines clinical obesity as “a chronic, systemic illness” caused by excess adiposity and preclinical obesity as excess adiposity with preserved organ function and an increased risk of progression. Causes are multifactorial, and family, twin, and adoption studies attribute at least 40% to 70% of the variation in body weight to genetic factors.
In measured data for U.S. adults from August 2021 to August 2023 (NCHS Data Brief), the prevalence of obesity was 40.3% (39.2% in men, 41.3% in women), highest at ages 40 to 59 years (46.4%), and the prevalence of severe obesity was 9.4%; a further 32.1% of adults were overweight (unadjusted). From 2013 to 2014 through 2021 to 2023, age-adjusted obesity prevalence did not change significantly, while age-adjusted severe obesity increased from 7.7% to 9.7%. In self-reported 2025 data, every state and territory with available data had an obesity prevalence above 25% except the District of Columbia (24.2%). Among 13,888 U.S. adults followed for 115,797 person-years, obesity incidence was 28.1 per 1,000 person-years in 2001 to 2017, rose by 18% in 2013 to 2017 compared with 2009 to 2013, and was 62.1 per 1,000 person-years in adults with overweight compared with 8.8 in adults with normal weight. Projections estimate obesity in 48.9% and severe obesity in 24.2% of U.S. adults by 2030. Worldwide in 2024, 2.6 billion adults were overweight, including 940 million (about 16%) with obesity.
In an individual-participant data meta-analysis of prospective studies, hazard ratios for all-cause mortality were 1.45 for obesity grade 1, 1.94 for grade 2, and 2.76 for grade 3. In a population-based United Kingdom cohort, life expectancy from age 40 years was 4.2 years shorter in men and 3.5 years shorter in women with a BMI of 30 or greater than in those of healthy weight. The WHO estimates that higher-than-optimal BMI caused 3.7 million deaths in 2023. In Finnish cohorts and the UK Biobank, obesity was associated with 21 diseases, with confounder-adjusted hazard ratios compared with healthy weight of 2.83 for developing at least one obesity-related disease and 12.39 for complex multimorbidity. Obesity is associated with 13 types of cancer that account for more than 40% of annual cancer diagnoses.
Summary: humanistic and economic burden
Systematic reviews of reviews report that obesity is associated with lower generic and obesity-specific health-related quality of life (HRQoL) in all populations studied, with physical HRQoL declining as BMI rises and mental component scores reduced only in class III obesity; an update identified eight systematic reviews or meta-analyses published since 2017 with consistent findings and none on anti-obesity medications. In U.S. national survey data, the median SF-12 physical component score was 55.86 in respondents of normal weight and 47.21 in those with class 3 obesity, and the proportion reporting an inability to work rose from 10.3% to 26.9%. In the National Health and Wellness Survey of 69,742 adults, the largest declines in HRQoL were generally observed between class 2 and class 3 obesity. The ICER obesity model applies a utility reduction of 0.006 per one-unit increase in BMI, and the ICER report describes weight bias in health care settings as “discouraging people from seeking care”. In an analysis of the STEP 1 and STEP 2 trials, 51.8% and 39.6% of participants receiving semaglutide 2.4 mg reached the meaningful within-person change threshold for IWQOL-Lite-CT Physical Function at week 68, compared with 28.3% and 29.5% receiving placebo.
Using Medical Expenditure Panel Survey data for 175,726 respondents (2019 U.S. dollars), obesity was associated with $1,861 in excess annual medical costs per adult, or $172.74 billion nationally, and severe obesity with $3,097 per adult. An instrumental-variable analysis estimated annual medical costs $2,505 (100%) higher in adults with obesity than in adults of normal weight, rising from 68.4% higher for class 1 to 233.6% higher for class 3, $2,868 higher with public insurance and $2,058 higher with private insurance, and $260.6 billion in aggregate in 2016. Among 719,482 employees, employer costs for absenteeism, short-term disability, long-term disability, and workers’ compensation were $1,036, $611, $38, and $95 higher per year in the class 3 obesity cohort than in the normal weight cohort. A modeling study estimated that a 5% weight loss would reduce annual health care spending by $670 (8%) in adults with employer-sponsored insurance and by $1,262 (7%) in Medicare beneficiaries with 1 or more comorbid conditions, and a 25% weight loss by $2,849 (34%) and $5,442 (31%), respectively. Globally, the economic impact of overweight and obesity was estimated at 2.19% of gross domestic product in 2019, projected to rise to 3.29% by 2060.